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Summary  Multidrug-resistant  tuberculosis  (MDR-TB),  the  prevalence  of  which  has
increased  across  the  globe  in  recent  years,  is  a  serious  threat  to  public  health.
Timely  diagnosis  of  MDR-TB,  especially  among  new  TB  cases,  is  essential  to  facilitate
appropriate  treatment,  which  can  prevent  further  emergence  of  drug  resistance  and
its  spread  in  the  population.  The  present  case  report  from  India  aims  to  address
some  operational  challenges  in  diagnosing  MDR-TB  among  new  cases  and  potential
measures  to  overcome  them.  It  argues  that  even  after  seven  years  of  implementing
the  DOTS-Plus  program  for  controlling  MDR-TB,  India  still  lacks  the  technical  capacity
for  rapid  MDR-TB  diagnosis.  The  case  report  underscores  an  urgent  need  to  explore
the  use  of  WHO-endorsed  techniques  such  as  Xpert  MTB/Rif  and  commercial  assays
such  as  Genotype  MTBDR  for  rapid  diagnosis  of  MDR-TB  among  new  cases.  Suitable
applications  may  be  found  for  other  TB  high-burden  countries  where  MDR-TB  is  a
major  concern.
©  2015  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Limited.  All  rights  reserved.∗ Tel.: +91 9850735008.
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ultidrug-resistant  tuberculosis  (MDR-TB)  is  a  con-
ition in  which  a  Mycobacterium  tuberculosis  strain
s resistant  to  at  least  two  ﬁrst-line  potent  anti-
B drugs  such  as  rifampicin  and  isoniazid.  MDR-TB
resents a threat  to  public  health  and  has  recently
nces. Published by Elsevier Limited. All rights reserved.
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Clearly  he  had  MDR-TB.  The  DOTS  Plus  program
for MDR-TB  management  was  launched  in  Indian  urgent  need  for  building  technical  capacity  for  r
ncreased  in  prevalence  worldwide  [1,2]. It  is
roblematic  because  it  requires  long-term  (18—24
onths)  and  expensive  treatment,  which  is  less
ffective  and  more  toxic  than  ﬁrst-line  treatment
3].  India  carries  the  highest  burden  of  TB  as  well
s MDR-TB  cases  among  notiﬁed  pulmonary  TB
ases and  hence  needs  serious  attention  [1]. The
lobal  Tuberculosis  Report  2014  noted  that  2.2%  (CI
.9—2.6) of  new  and  15%  (CI  11—19)  of  previously
reated TB  cases  in  India  were  MDR-TB;  according
o this  report,  the  estimated  burden  of  MDR-TB
n India  is nearly  61,000  cases  with  20,000  (CI
7,000—24,000) new  and  41,000  (CI  30,000—52,000)
reviously treated  cases  [1]. Because  prior  anti-TB
reatment  is  a  major  risk  factor  that  is  associ-
ted with  MDR-TB  [4],  previously  treated  cases
emain the  focus  of  MDR-TB  control  programs.
evertheless,  attending  MDR-TB  among  new  cases
s equally  important,  especially  in  India  for  sev-
ral reasons.  Diagnosed  new  TB  cases  are  often
nitially treated  in  the  weakly  regulated  private
ector and/under  the  Revised  National  TB  Control
rogram  (RNTCP).  Private  providers  are  known  to
eviate from  the  program  guidelines  [5,6]  and  often
rescribe  monotherapy  or  inadequate  treatment.
onversely, some  patients  receive  inadequate  anti-
B treatment  due  to  their  inability  to  afford  full
reatment  in  the  private  sector.  Some  patients
reated under  the  RNTCP  may  also  receive  inade-
uate  anti-TB  treatment  as  a  result  of  treatment
nterruption due  to  reasons  such  as  social  prob-
ems, early  symptomatic  relief  or  no  symptomatic
elief. These  scenarios  eventually  give  rise  to  the
mergence  of  anti-TB  drug  resistance.  Those  who
ave ‘primary  MDR-TB’  (i.e.,  an  initial  infection
ith an  MDR-TB  strain  prior  to  starting  any  anti-TB
reatment) fail  the  ﬁrst-line  treatment  regimen  and
ventually  die  or  may  develop  resistance  to  other
rugs besides  isoniazid  and  rifampicin  via  ‘ampli-
cation  of  resistance’  [7].  Lastly,  in  the  absence
f appropriate  treatments  for  MDR-TB,  mycobac-
erial strains  from  these  MDR-TB  cases  continue  to
ransmit in  the  population  and  thus  present  a  threat
o public  health.  To  prevent  emergence  and  spread
f MDR-TB,  its  timely  diagnosis,  especially  among
ew cases,  is  one  of  the  most  essential  steps.  How-
ver, there  are  operational  challenges  for  timely
DR-TB diagnosis.  The  present  case  report  aims  to
ddress some  of  them  along  with  potential  meas-
res to  overcome  these  challenges.ethods
his  case  report  belongs  to  a  patient  who  was  ini-
ially diagnosed  with  TB.  His  sputum  sample  was d diagnosis  of  MDR-TB  among  new  cases  503
ollected  as  a part  of  a larger  epidemiological
tudy  that  was  conducted  in  Maharashtra  state  dur-
ng 2004—2007.  Ethics  approval  for  this  study  was
rovided  by  the  Institutional  Ethics  Committee  of
he Foundation  for  Medical  Research,  Mumbai.  The
uthor personally  conducted  an  in-depth  interview
f this  patient  after  seeking  his  appropriate  writ-
en consent.  The  interview  was  conducted  in  two
ittings  during  2006—2007;  however,  only  a  part  of
he interview  was  utilized  here  to  contextualize  this
ase report.
 case of MDR-TB
ajaram  was  a 49-year-old  man  and  a resident  of  a
illage in  the  Pune  district  of  Maharashtra  State.  He
wned a small  piece  of  land,  but  income  from  the
and was  not  sufﬁcient  for  his  family,  which  included
is parents,  wife  and  a son.  Therefore,  he  went  to
umbai2 and  sought  a  welding  job.  However,  he  was
lone and  detached  from  his  family,  so  he  quickly
ecame addicted  to  liquor  and  smoking.  He  spent
early 20  years  in  Mumbai  during  which  he  occa-
ionally used  to  visit  his  village  and  family  with  a
oung son.  After  20  years,  he  permanently  returned
o his  village.  Within  a  few  months  after  his  return,
e started  coughing  and  had  a fever.  Initially,  he
ent to  a  private  doctor,  but  even  after  10—15  days
reatment, he  could  not  get  symptomatic  relief.
he doctor  referred  him  to  a nearby  government
ealth center,  where  he  was  diagnosed  with  TB  and
tarted a Category-I  regimen  (comprising  of  isoni-
zid, rifampicin,  ethambutol  and  pyrazinamide)  as
 ‘new  case’  per  India’s  Revised  National  TB  Con-
rol Program  (RNTCP)  guidelines  [8]. He  was  treated
ith the  above-mentioned  ﬁrst-line  regimen  for  six
onths. However,  his  cough  recurred  within  three
onths  after  he  ﬁnished  his  course  of  treatment.
is condition  became  so  serious  that  his  family  took
 decision  to  shift  him  to  a tertiary  care  center  in
une city.  There  he  was  treated  with  Category-II
retreatment)  regimen,  which  contained  strepto-
ycin  in  addition  to  the  regimen  described  above.
fter approximately  three  months,  Rajaram  died
n that  hospital.  The  drug  susceptibility  test  (DST)
esults of  his  sputum  sample  that  was  collected
rior to  starting  treatment  (as  a  part  of  a  research
roject)  indicated  that  Rajaram  was  infected  with
 strain  that  was  resistant  to  all  ﬁrst-line  drugs.2 A metropolitan city and ﬁnancial capital of India. It is a
ensely crowded city, noted as TB hyper endemic area.
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from  2007  onwards;  however,  when  this  patient
was treated,  there  was  no  facility  to  diagnose  and
treat MDR-TB  under  the  RNTCP.  Therefore,  he  was
treated  with  the  Category  II  regimen  only.
Discussion
While  a  social  analysis  may  be  useful  to  understand
the context  and  role  of  predisposing  factors  such
as poverty,  the  migration  to  Mumbai  (TB  hyper-
endemic city)  and  substance  abuse  that  led  to  TB,
the death  of  this  patient  is  a  much  serious  concern
that needs  attention.  An  early  diagnosis  of  MDR-TB
could not  happen  in  this  case  because  only  a  sputum
smear  microscopy  was  conducted  for  TB  diagnosis
per the  program  guidelines,  and  there  was  no  DST
conducted  prior  to  starting  anti-TB  treatment.
Although  this  case  report  dates  back  to
2006—2007, when  the  DOTS  Plus  program  for  MDR-
TB management  was  not  in  place  in  India,  it  remains
relevant  even  today.  This  is because  after  seven
years of  implementing  the  DOTS-Plus  program,  the
RNTCP guidelines  still  do  not  recommend  DST  prior
to initiating  anti-TB  treatment  in  new  cases  except
for TB  cases  in  the  contacts  of  conﬁrmed  MDR-TB
cases [9].  This  may  also  indicate  that  the  RNTCP
still  lacks  sufﬁcient  facilities  to  perform  DST  among
all new  cases.  As  seen  from  Rajaram’s  case,  even
today,  all  new  cases  are  treated  with  the  ﬁrst-
line regimen  without  having  DST  results  prior  to
starting anti-TB  treatment,  which  continues  until
they no  longer  respond  (i.e.,  until  they  are  spu-
tum positive  after  ﬁve  months  of  treatment  with
the ﬁrst-line  regimen).  Their  sputum  sample  is  sent
for culture  and  DST  only  after  it  is  suspected  that
they have  MDR,  and  it  may  take  up  to  8—12  weeks
to get  a  diagnosis  using  conventional  methods  for
culture  and  DST  [10]. The  delay  in  obtaining  a diag-
nosis not  only  deteriorates  the  patient’s  health  but
also eventually  increases  the  risk  of  transmission  of
MDR-TB strains  to  the  population.  Our  operational
research study  in  Maharashtra  state  reported  that
13% of  new  TB  cases  in  Mumbai  city  and  9%  in  rural
areas had  prior  anti-TB  treatment  for  >1  month
and yet  they  were  erroneously  classiﬁed  as  ‘new’
due to  lack  of  patient  screening  by  the  RNTCP  staff
and non-reporting  by  patients  [11].  Such  so  called
‘new’ cases  that  have  been  previously  treated  also
need serious  attention  especially  in  the  context
of MDR-TB  emergence,  as  explained  in  the  ear-
lier paragraphs.  Farmer  and  colleagues  previously
attributed MDR-TB  emergence  to  ‘structural  vio-
lence’. This  term  refers  to  social  arrangements
that put  individuals  and  population  at  harm  [12].
2
e
nS.  Atre
s  observed  in  this  case  report,  operational  barri-
rs, lacunae  in  the  program  guidelines  and  limited
nfrastructure for  conducting  DST  for  rapid  MDR-
B diagnosis  among  new  cases  are  nothing  but
ypical  reﬂections  of  ‘structural  violence’,  which
re at  the  root  of  problems  such  as  MDR-TB  in
ndia.
Although the  present  communication  is  based
n a  single  case  report,  it  represents  a  com-
on scenario  for  all  new  cases  for  whom  DST
ould not  be  conducted  prior  to  starting  anti-
B treatment.  This  study  underscores  an  urgent
eed for  revisiting  program  guidelines  and  build-
ng technical  capacity  for  rapid  MDR-TB  diagnosis
rior  to  initiating  anti-TB  treatment  to  facilitate
ts timely  and  appropriate  treatment.  There  are
apid diagnostic  methods  such  as  Xpert  MTB/Rif
nd commercial  assays  such  as  Genotype  MTBDR
nd Genotype  MTBDRPlus  (Hain  Lifescience,  GmbH,
ermany),  which  have  been  labeled  for  use  on
acterial  isolates  that  have  been  obtained  directly
rom smear  positive  pulmonary  specimens.  These
ethods  can  offer  results  in  a few  hours/days
ompared with  conventional  methods,  which  take
pproximately  8—12  weeks  [10,13]. Currently,  X-
ert MTB  facilities  are  available  at only  54  sites
n India  [1].  Potential  use  of  such  methods  should
e explored  to  suspect  and  start  MDR-TB  treat-
ent in  high-burden  settings  such  as  India,  which
till have  limited  DST  facilities.  Further  research  is
eeded to  understand  operational  as  well  as  cost
ssues in  expanding  these  types  of  methods  not
nly in  India  but  also  in  other  countries.  These
apid diagnostic  measures  can  beneﬁt  patients
s well  as  programs  responsible  for  MDR-TB  con-
rol.
eclaration
his  case  report  is based  on  an  interview  that  the
uthor conducted  himself  as  a  part  of  his  doctoral
esearch work,  which  has  been  submitted  to  the
epartment  of  Anthropology,  University  of  Pune.
he entire  manuscript  and  case  report  interpreta-
ion was  performed  by  the  author  himself.  A  part
f writing  of  this  article  was  undertaken  by  the
uthor  while  he  was  a Fulbright-Nehru  Post  doc
ellow  at  the  Department  of  Global  Health  and
ocial Medicine  at Harvard  Medical  School  during
013—14.  He  is solely  responsible  for  the  views
xpressed in  this  communication.
Note:  For  conﬁdentiality  purposes,  the  patient’s
ame has  been  changed.
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